Table 3.
HRs (95% CIs) for VTE per 10-μg/m3 increase in PM.a
| Averaging period (days) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|---|---|---|
| PM2.5 | ||
| 1 | 1.01 (0.88–1.16) | 1.04 (0.89–1.22) |
| 7 | 0.97 (0.78–1.20) | 1.00 (0.78–1.28) |
| 30 | 0.99 (0.76–1.29) | 1.02 (0.73–1.43) |
| 365 | 1.03 (0.66–1.62) | 0.93 (0.54–1.60) |
| PM10 | ||
| 1 | 0.94 (0.86–1.03) | 0.98 (0.88–1.10) |
| 7 | 0.88 (0.76–1.02) | 0.91 (0.77–1.08) |
| 30 | 0.87 (0.71–1.05) | 0.93 (0.74–1.16) |
| 365 | 0.92 (0.65–1.29) | 1.05 (0.72–1.53) |
a
Models were stratified by birth cohort (in 5-year increments) and trial arm. Adjusted models include race/ethnicity, education, BMI, coronary heart disease, peripheral arterial disease, stroke, cancer, fracture, aspirin or NSAID use, hypercholesterolemia, current smoking, physical activity, hormone therapy treatment arm (active vs. placebo), treatment duration (years), and temperature (degrees centigrade).